
    
      Superiority of HDT with autologous stem cell transplantation (ASCT) in the upfront treatment
      of poor-risk DLBCL remains an option for intermediate-high (IH) or high IPI young adults. We
      updated results of the prospective trial Goelams 074 to evaluate long-term efficacy and
      toxicity in 42 patients who underwent HDT with ASCT.
    
  